RT Journal Article
SR Electronic
T1 FDA oversight of NSIGHT genomic research: the need for an integrated systems approach to regulation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 19001370
DO 10.1101/19001370
A1 Laura V. Milko
A1 Flavia Chen
A1 Kee Chan
A1 Amy M. Brower
A1 Pankaj B. Agrawal
A1 Alan H. Beggs
A1 Jonathan S. Berg
A1 Steven E. Brenner
A1 Ingrid A. Holm
A1 Barbara A. Koenig
A1 Richard B. Parad
A1 Cynthia M. Powell
A1 Stephen F. Kingsmore
YR 2019
UL http://medrxiv.org/content/early/2019/07/30/19001370.abstract
AB The National Institutes of Health (NIH) funded the Newborn Sequencing In Genomic medicine and public HealTh (NSIGHT) Consortium to investigate the implications, challenges and opportunities associated with the possible use of genomic sequence information in the newborn period. Following announcement of the NSIGHT awardees in 2013, the Food and Drug Administration (FDA) contacted investigators and requested that pre-submissions to investigational device exemptions (IDE) be submitted for the use of genomic sequencing under Title 21 of the Code of Federal Regulations (21 CFR) part 812. IDE regulation permits clinical investigation of medical devices that have not been approved by the FDA. To our knowledge, this marked the first time the FDA determined that NIH-funded clinical genomic research projects are subject to IDE regulation. Here we review the history of and rationale behind FDA oversight of clinical research and the NSIGHT Consortium’s experiences in navigating the IDE process. Overall, NSIGHT investigators found that FDA’s application of existing IDE regulations and medical device definitions aligned imprecisely with the aims of publicly funded exploratory clinical research protocols. IDE risk assessments by the FDA were similar to, but distinct from, protocol risk assessments conducted by local Institutional Review Boards (IRBs), and had the potential to reflect novel oversight of emerging genomic technologies. However, the pre-IDE and IDE process delayed the start of NSIGHT research studies by an average of 10 months, and significantly limited the scope of investigation in two of the four NIH approved projects. Based on the experience of the NSIGHT Consortium, we conclude that policies and practices governing the development and use of novel genomic technologies in clinical research urgently need clarification in order to mitigate potentially conflicting or redundant oversight by IRBs, NIH, FDA, and state authorities.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialThis manuscript does not involve a clinical trialFunding StatementThe NSIGHT consortium was funded by National Institute of Health grants U19HD077693, U19HD077632, U19HD077627, and U19HD077671. The Newborn Screening Translational Research Network is funded through a contract from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (HHSN275201800005C). No external funding was received from a third party for any aspect of the submitted work (including but not limited to grants, data monitoring board, study design, manuscript preparation, statistical analysis, etc.)Author DeclarationsAll relevant ethical guidelines have been followed and any necessary IRB and/or ethics committee approvals have been obtained.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.Not ApplicableAny clinical trials involved have been registered with an ICMJE-approved registry such as ClinicalTrials.gov and the trial ID is included in the manuscript.Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant Equator, ICMJE or other checklist(s) as supplementary files, if applicable.Not ApplicableNo data is referred to in the manuscript.